Interstitial Lung Disease Trial, Recruiting NCT04676828 Sponsor: University of Aarhus Condition: Interstitial Lung Disease
Back to Interstitial Lung Disease

Interstitial Lung Disease Trial, Recruiting

NCT04676828
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with lung cancer (either small-cell or non-small-cell type), confirmed by a tissue sample test
  • You have been referred for radiation treatment with the goal of curing the cancer
  • You are planned to receive a radiation dose of 60–66 Gy in standard-sized sessions, though other dose plans may also be accepted depending on the treatment centre
  • You may be receiving chemotherapy at the same time as your radiation treatment
  • You have a small number of cancer spots that have spread to other areas, but those have already been removed or treated with radiation
  • Your radiation treatment is targeting the cancer in the chest area, with the aim of curing it
  • You are 18 years of age or older and have agreed to take part by signing and verbally confirming your consent

Who may not be able to join:

  • You are currently receiving immunotherapy treatment at the same time as radiation
  • You have had radiation treatment to your chest area in the past
  • You have another cancer that is not currently under control
  • You have any personal, psychological, family, social, or location-related circumstances that might make it difficult to follow the study requirements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +61 412695410

Australian sites

Sydney West Radiation Oncology Network Westmead and Blacktown Hospitals, Sydney, New South Wales
+61 432207880

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 December 2021
Est. completion
1 December 2027

Where this trial is recruiting

🇦🇺 Australia 🇩🇰 Denmark

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Radiation-induced lung toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov